Bobak R. Azamian - 15 Mar 2025 Form 4 Insider Report for Tarsus Pharmaceuticals, Inc. (TARS)

Role
President/CEO and Board Chair, Director
Signature
/s/ Jeffrey Farrow, Attorney-in-Fact
Issuer symbol
TARS
Transactions as of
15 Mar 2025
Net transactions value
$0
Form type
4
Filing time
18 Mar 2025, 21:40:15 UTC
Previous filing
07 Mar 2025
Next filing
20 Mar 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TARS Common Stock Options Exercise +51,395 +194% 77,851 15 Mar 2025 Direct F1
holding TARS Common Stock 830,106 15 Mar 2025 By the Bobak Azamian Living Trust established April 16, 2018 F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TARS Restricted Stock Units Options Exercise $0 -11,299 -50% $0.000000 11,300 15 Mar 2025 Common Stock 11,299 Direct F3, F4
transaction TARS Restricted Stock Units Options Exercise $0 -16,975 -33% $0.000000 33,950 15 Mar 2025 Common Stock 16,975 Direct F3, F5
transaction TARS Restricted Stock Units Options Exercise $0 -23,121 -25% $0.000000 69,364 15 Mar 2025 Common Stock 23,121 Direct F3, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs").
F2 The Reporting Person is the trustee of the Bobak Azamian Living Trust, established April 16, 2018 and has voting and dispositive power with respect to these shares.
F3 Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company's common stock.
F4 RSUs granted on March 9, 2022, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2023, 2024, 2025 and 2026, subject to the Reporting Person's continuous service.
F5 RSUs granted on March 8, 2023, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2024, 2025, 2026 and 2027, subject to the Reporting Person's continuous service.
F6 RSUs granted on March 7, 2024, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2025, 2026, 2027 and 2028, subject to the Reporting Person's continuous service.